Epidemiology of SARS-CoV-2 and Mortality to Covid19 Disease in French Cancer Patients
To determine the prevalence and the 3-months incidence of SARS-CoV-2 in cancer patients (Part A).

To evaluate the Covid-19 disease-specific mortality rate in cancer patients treated by hydroxychloroquine and azithromycin (Part B).
Cancer & COVID 19
DRUG: Hydroxychloroquine|DRUG: Azithromycin
Prevalence and the 3-months incidence of SARS-CoV-2 in cancer patients, Up to 3 months|Covid-19 disease-specific mortality rate in cancer patients treated by hydroxychloroquine and azithromycin, Up to 12 months
To determine the prevalence and the 3-months incidence of SARS-CoV-2 in cancer patients (Part A).

To evaluate the Covid-19 disease-specific mortality rate in cancer patients treated by hydroxychloroquine and azithromycin (Part B).